Dr. Schorge was born and raised in mid-Michigan. He enrolled in the Honors Program at the University of Michigan, where he became a life-long Wolverines fan and met his future wife. He had a brief immersion in Southern culture during medical school at Vanderbilt University. Dr. Schorge next served an OB/GYN resident at the integrated Brigham & Women's Hospital-Mass General program before completing a gynecologic oncology fellowship at 'the Brigham'. He was on the faculty at the University of Texas Southwestern Medical School-Parkland Memorial Hospital in Dallas for eight years before returning to Boston as Chief of GYN Oncology at Mass General. Dr. Schorge has been married for 20+ years and has three children. He is a member of Red Sox Nation and the entire family proudly wear Tom Brady jerseys [U-Michigan alumnus].
Dr. Schorge discusses the new pap smear guideline's in this March 16, 2012 interview on Boston's Fox 25 news program.
ResearchDr. Schorge's research interests primarily focus on ovarian cancer. He was the lead author on the 2010 Society of Gynecologic Oncology White Paper describing the etiology, screening and surveillance of this disease. He has spearheaded the investigation of the clinical benefits of cytoreductive surgery and incorporation of ultra-radical techniques to achieve prolonged survival for patients with advanced disease at Mass General - where the concept of aggressive debulking was initially described in the 1930s. He is co-Director of the the GYN ONC tissue repository where patient samples are tested for efficacy of novel treatments [under the supervision of Drs. Bo Rueda, Rosemary Foster and Whit Growdon]. Dr. Schorge is also a committee member of the Gynecologic Oncology Group and serves as the Principal Investigator at Mass General for a therapeutic GOG trial in patients with advanced ovarian cancer. His clinical experience and dedication to education is exemplified by his serving as the lead editor of Williams' Gynecology, a 1500+ page text with surgical atlas.
Schorge JO, Garrett LA, Goodman A. Cytoreductive surgery for advanced ovarian cancer: quo vadis? Oncology 2011;25:928-34.
Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM 2nd, Horowitz NS, Del Carmen MG, Schorge JO. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol 2011 Oct 13.
Schorge JO, Bradford LS, del Carmen MG. Primary cytoreductive surgery for advanced ovarian cancer: is it the past, present, or future? Clin Adv Hematol Oncol 2011;9:912-8.
McCann CK, Growdon WB, Munro EG, Del Carmen MG, Boruta DM, Schorge JO, Goodman A. Prognostic significance of splenectomy as part of initial cytoreductive surgery in ovarian cancer. Ann Surg Oncol 2011;18:2912-8.
Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, Herzog TJ. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol. 2010;119:7-17.
Schorge JO, Wingo, SN, Bhore R, Heffernan TP, Lea JS. Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynaecol Obstet. 2010;108:123-7.
John Schorge, MD, chief of the Massachusetts General Hospital Gynecologic Oncology Division, discusses the types of treatment options available for patients with reproductive cancers.
A recap of the Ovarian Cancer Survivors Course